Antiinflammatory therapy has been shown to reduce the adverse pathophysiological consequences that occur in bacterial meningitis and to improve outcome from disease. In the present study, modulation of two principal steps of the meningeal inflammatory cascade was accomplished by concomitant administration of dexamethasone to diminish overproduction of cytokines in response to a bacterial stimulus and of a monoclonal antibody directed against adhesion-promoting receptors on leukocytes to inhibit recruitment of white blood cells into the subarachnoid space. Dexamethasone and antibody therapy produced a marked attenuation of all indices of meningeal inflammation and reduction of brain water accumulation after H.
Introduction
Antiinflammatory therapy of animals and humans with bacterial meningitis has been shown to decrease meningeal inflammation, blood-brain barrier permeability, intracranial hypertension, brain edema, tissue damage, long-term neurological sequelae, and mortality rates associated with this disease (1, 2) . Likewise, the transient enhancement of the host's inflammatory response that commonly follows initiation of antibiotic treatment has been significantly attenuated when agents have been used that selectively interfere with production of inflammatory mediators (e.g., dexamethasone, cyclooxygenase inhibitors) or with influx of leukocytes into the subarachnoid space (e.g., pentoxifylline, anti-CD 1 8 receptor antibodies) (3) (4) (5) (6) .
Elevated concentrations of proinflammatory substances such as TNF and IL-1 trigger initiation of the inflammatory process and provoke profound pathophysiological changes that result in alteration of cerebrospinal fluid (CSF)l hydrodynamics and in activation of the metabolic and coagulation pathways (7) (8) (9) . Dexamethasone has been shown to inhibit production of these cytokines at transcriptional and translational levels, especially when given before liberation of active bacterial components into the subarachnoid space (10, 1 1).
Influx of leukocytes into CSF can further amplify these pathophysiologic events because their accumulation contributes to a sluggish CSF circulation and decreased resorption, and because of liberation of cytotoxic products on degranulation (12) . Before entering the subarachnoid space leukocytes must adhere to brain endothelial cells presumably through a family ofadhesion-promoting receptors and ligands located on leukocyte cell membranes and endothelium that have been previously activated by exposure to cytokines (13, 14) . Treatment of experimental lapine meningitis induced by intracisternal inoculation ofliving bacteria (e.g., S. pneumoniae, H. influenzae, N. meningitidis), their cell wall components (e.g., teichoic acid, lipopolysaccharide), or by human cytokines with monoclonal antibodies (MAbs) directed against the CDl 1/CD 1 8 leukocyte adhesion receptors was shown to decrease transendothelial passage of polymorphonuclear cells into CSF and to reduce significantly indices of meningeal inflammation (6, 15) . The use of anti-CD18 MAbs has also been shown to inhibit polymorphonuclear leukocyte accumulation and plasma leakage in rabbits with experimentally-induced inflammatory skin lesions (16) and to reduce multiple organ injury and death caused by increased leukocyte adhesiveness in an experimental model of generalized ischemia-reperfusion injury (17) .
The aim of this study was to assess whether the combination ofdexamethasone (DXM) and anti-CD 1 1/CD 18 antibodies would be more effective than either agent alone in preventing or attenuating the pathophysiologic events that occur in experimental meningitis induced by H. influenzae type b or its purified lipooligosaccharide (LOS).
Methods

Preparation ofHib endotoxin
Hib endotoxin (LOS) was purified from cells of Hib strain DL42 by using the hot phenol-water method of Westphal and Jann (18) , as modified by Johnson and Perry (19) . The purity of this LOS preparation was confirmed by SDS-PAGE, followed by silver staining (20) and Western blot analysis using hyperimmune rat serum to Hib DL42 (21) . 20 ng of the endotoxin, which is contained in 2 X 106 bacterial cells, was chosen as the inoculum to induce meningitis because this amount has consistently induced meningeal inflammation in this rabbit model (22) and because CSF samples from patients with Hib meningitis contain from 104 to I0' CFU/ml.
Bacterial strain
Hib strain DL42 is a non-fl-lactamase-producing strain isolated from the CSF of a child with meningitis. This strain is fully virulent in the infant rat model for Hib invasive disease and belongs to LOS antigenic group 2, which is the predominant LOS antigenic type among invasive Hib isolates (23) . The minimum inhibitory concentration of ceftriaxone for this Hib strain was 0.01 fIg/ml.
A final inoculum of -1 x 106 colonies/ml taken from a culture which contained bacteria in a log phase of growth was prepared. Animals were then intracisternally inoculated with 0.2 ml of this bacterial suspension. The rabbit model of experimental meningitis, originally described by Dacey and Sande (24) , was used in a modified form. New Zealand White male rabbits (2-3 kg) were anesthetized with intramuscular injections of ketamine (40 mg/kg) and acepromazine (3 mg/kg) and placed in a stereotactic frame. A spinal needle was introduced into the cisterna magna and 0.2 ml ofCSF withdrawn. Animals were then inoculated with same volume of either Hib LOS or live Hib organisms. Subsequent CSF samples (0.2-0.3 ml) were obtained at different times according to study design. Immediately after collection, the CSF aliquots were analyzed for cell count and the remaining CSF was centrifuged at 5,000 rpm for 5 min, and the supernatants stored at -70'C until assayed for lactate, protein, and TNFa activity. In experiments involving use of live organisms, bacterial densities in CSF were determined by standard bacteriologic techniques. Blood samples were also obtained at different times through auricular arterial punctures and processed for leukocyte counts and bacterial density determinations.
Experimental meningitis model
Antibiotic and antiinflammatory products
An intravenous injection of 100 mg/kg of ceftriaxone (Hoffmann-LaRoche, Inc., Nutley, NJ) was used. CSF and serum concentrations of antibiotic were measured by a validated (25) 15 min before administration of ceftriaxone. Aliquots of CSF were obtained at 6 h (just before antibiotic treatment), 1 18 , and some at 24 h after bacterial challenge and analyzed for leukocyte counts, bacterial densities, and for protein, lactate, and TNFa concentrations. Ceftriaxone concentrations in CSF and serum were also determined in some of these animals. Eight rabbits each from groups 2-5 were sacrificed at 18 h (12 h after antibiotic therapy) for determination of brain water content. In addition, aliquots of 1 ml of blood were withdrawn at concordant times with CSF removal and analyzed for leukocyte and bacterial colony counts. To assess the effects of higher doses of IB4 MAbs on meningeal inflammation and brain edema six animals received intravenously a dose of2.5 mg/kg and three rabbits were treated with a dose of 5 mg/kg.
Measurement ofbrain water content
18 h after induction of meningitis the animals were sacrificed by an overdose (150 mg per rabbit) ofpentobarbital given intravenously. Immediately after death, a craniotomy was performed, and the brain, without the cerebellum and medulla, was removed and weighed in aluminum boats. The brain was then dried to stable weight (5-7 d) in a vacuum oven (Precision Scientific Group, Chicago, IL) at a temperature of 105'C and a vacuum of -50 to -60 kPa. For comparison, 15 uninfected rabbits were killed, and their brain water contents were measured. Additionally, 12 brains of uninfected animals that received either DXM (1 mg/kg) or IB4 MAbs (1 mg/kg) were weighed 12 h after antiinflammatory treatment. The brain water content, expressed as grams ofwater per 100 g ofdry weight, was determined and used as an estimate of brain edema. The brain water content was calculated by using the following formula: brain water content = (wet weight -dry weight)/dry weight X 100.
Cytolytic assayfor TNFa
TNFa activity was determined by a previously described cytotoxic assay (27) . Briefly, CSF samples were added to 96-2311 ELISA plates containing 7 x 104 L929 cells/well and the degree of cytotoxicity was quantified spectrophotometrically (490 nm). Equivalent concentrations ofTNFa were determined for experimental samples by interpolation ofknown concentrations ofrabbit TNFa run simultaneously (1 pg to 1 qg/ml). The minimal amount of detectable TNFa activity using these conditions was 10 pg/ml. The specificity of the results was confirmed by adding an anti-rabbit TNFa monoclonal antibody to positive samples and documentation ofcomplete neutralization ofcytotoxicity. TNFa activity in CSF from healthy, uninfected rabbits was below the limits of detectability (3) .
Measurement ofinflammatory indices
Leukocyte counts in CSF and blood were determined by the use of a Neubauer hematocytometer (American Optical, Buffalo, NY). Samples were also stained with Wright solution to evaluate leukocyte histology.
Lactate concentrations in CSF were determined by a kinetic enzymatic method that used the reaction oflactate with nicotinamide-adenine dinucleotide (NAD) in the presence of lactate dehydrogenase to produce NAD, reduced NADH, and pyruvate. The production of NADH was quantified spectrophotometrically (340 nm). The precision ofthe method was tested by running a known standard of40 mg/dl 10 times in 1 d. The coefficient of variation was around 2%.
Protein concentrations in CSF were measured by a modified biuret assay on the Ektachem 700 (Eastman Kodak Co., Rochester, NY). In this method, protein in a moderately alkaline solution chelates Cu++ ions from an azo dye, resulting in a spectral shift. The decrease in absorbance of the copper-azo dye complex is related to the concentration of protein in the sample. This method detects albumin and globulins.
Statistical analysis
Multiway repeated measures analysis of variance (ANOVA) was used to assess the effect of independent treatments with time for the following variables: leukocytes, protein, and lactate concentrations, log CFU/ ml of Hib organisms in CSF, and CSF concentrations of ceftriaxone. (Table I) .
Lactate concentrations in CSF were also significantly reduced over time when DXM was given either alone or in combination with IB4 MAbs. Similar high mean lactate values were detected in the other three groups.
Administration of either IB4 MAbs, DXM, or the combination of both, was accompanied by a significant attenuation of mean CSF protein concentrations over time compared with those in the other two groups. Experiment 2 (nonantibiotic treated H. influenzae-induced meningitis). Animals receiving combination therapy with IB4 MAbs plus DXM showed a highly significant over time reduction in CSF pleocytosis, protein, lactate, and TNTFa concentrations compared with those values observed in the untreated control group. In addition, leukocyte, TNFa, and lactate concentrations were also significantly lower when both agents were given together compared with results in animals that received IB4 MAbs alone. The peak values of all these inflammatory indices were detected at 12 h after intracisternal inoculation of live H. influenzae organisms (Table II) .
A higher CSF multiplication of bacteria was seen in those animals that received IB4 MAbs. This finding, however, was only significant for the combination therapy compared with those values observed in rabbits assigned to the control untreated group (Table II) . Although comparable bacterial densities were detected in blood cultures of all three groups taken at similar times (6 h, 12 h) as CSF, bacteremia (6 h) was present early in 11 of 11 (100%) untreated animals compared with in seven of 11 (67%) and in six of 11 (56%) rabbits receiving IB4 MAbs and IB4 + DXM, respectively (P = 0.015, Fisher's test comparing IB4-treated with untreated rabbits).
The mean brain water content values were similar in both treated groups of animals and substantially lower than those measured in untreated control rabbits (Table II) . The difference in values was significant for only those animals that received combined therapy. Normal brain water content measured in 14 uninfected animals was 400.1 ± 11.8 g ofwater/100 g of dry weight. Likewise, similar brain water contents were measured in eight uninfected rabbits 12 h after treatment with DXM and six uninfected animals treated with IB4 MAbs (data not shown).
There was a significant increase in blood leukocyte counts when animals were treated with IB4 MAbs (normal values in rabbits are from 6,000 to 10,000 WBCs/mm3), either with or without DXM, compared with values in the control group. In the latter group leukopenia was detected at 6 h (mean± 1 (Figs. 1-3) . The peak values of these inflammatory indices were detected at 6 h after ceftriaxone therapy for lactate and protein concentrations, at 12 h for leukocyte counts, and at 2 h for TNFa activity (Table III) . The significant attenuating effect of combined therapy on meningeal inflammation is apparent. Likewise, a substantial reduction in brain water content was obtained in the DXM plus IB4 therapy group compared with that in the other groups (Table III) . When each antiinflammatory agent was given alone, however, a significantly lower brain water content was observed compared with that in animals given ceftriaxone therapy only. Table IV shows the CSF bacterial densities at different times after onset ofantibiotic treatment. Similar CSF bacterial clearance rates were observed in all antibiotic-treated animals regardless of the antiinflammatory modality employed. Three to four log reductions in CSF bacterial counts were detected by 12 h after onset of antibiotic treatment and by 18 h all treated animals had sterile CSF.
All animals before onset ofceftriaxone treatment were bacteremic and had similar bacterial counts in blood cultures. By 6 h after initiation of antibiotic therapy all treated animals, regardless of antiinflammatory drug assignment, had sterile blood cultures.
Serum ceftriaxone concentrations were similar in all groups of animals. They ranged from 41.5 to 60.1 gg/ml 6 h after antibiotic administration and from 1.2 to 4.5 Atg/ml at 24 h.
Lower concentrations were detected, however, in CSF of ani- MAbs were detected in CSF at 6 or 12 h after their intravenous administration. Peripheral leukocytosis (with > 90% polymorphonuclear cells) was observed in rabbits receiving IB4 MAbs therapy, either alone or combined with DXM, with maximal leukocyte counts of 18,667±5,193, and 20,417+3,878 white blood cells/ mm3, respectively, seen at 12 h after onset ofantibiotic therapy compared with 7,500±4,600, and 9,800+3,300 for animals that received CTX only, and CTX plus DXM, respectively (P < 0.05, ANOVA over time). Ofall treated animals followed for 24 h (six rabbits in each group), only one died. This rabbit received antibiotic therapy alone. The remaining animals were alive and looked well. As stipulated by our Institutional Review Board for Animal Research the animals were sacrificed soon after completion of the experiments.
An additional two sets of experiments involving 14 rabbits were conducted to assess the effect ofhigher IB4 MAb doses on meningeal inflammation and brain edema. There were no statistically significant enhanced antiinflammatory effects when larger doses of IB4 MAbs were administered compared with results after the 1 mg/kg dose (Table VI) despite achievement ofconsiderably higher IB4 serum concentrations 2 h after antibody administration; mean serum IB4 concentrations were 14.1±4.5, 25.5±7.7, and 66.8±13.6 Ag/ml for the 1, 2.5, and 5 mg/kg doses, respectively, whereas at 12 h values of 7.1±3.1, 17.4+5.6, and 35.4±7.9 ,ug/ml, respectively, were detected.
Discussion
It is now recognized that further improvements in outcome from bacterial meningitis will most likely not come from the (30, 31) . Antiinflammatory drugs that already have been tested in experimental models of bacterial meningitis have included agents targeted to interfere either with one or more mediators of the inflammatory cascade or with recruitment of leukocytes across the blood brain barrier. Data generated in this study showed that a combination of both therapeutic approaches attenuated dramatically the principal indices of CNS inflammation that are measured in bacterial meningitis. These profound antiinflammatory effects of combination therapy with DXM and IB4 MAbs were not caused by different pharmacokinetics of IB4 MAbs resulting from treatment with DXM because plasma concentrations and half-lives ofIB4 MAbs were similar whether or not DXM was concomitantly administered. In addition, increasing the dose of IB4 MAbs did not reduce meningeal inflammation compared with that after DXM plus 1 mg/ kg IB4 or 1 mg/kg IB4 alone, suggesting that the addition of dexamethasone to reduce cytokine overproduction contributed substantially to the profound modulation observed with combination therapy. It is unknown whether dexamethasone affects expression ofCD 18-independent adhesion receptors on brain endothelium and/or leukocyte surfaces which has been described for PMN adherence in the pulmonary circulation (32) .
Influx of PMNs into CSF was significantly reduced when either dexamethasone or anti-CD18 monoclonal antibodies were given separately but it was further decreased following concomitant administration of both agents. To enter the subarachnoid space, PMNs must first adhere to the cerebral capillary endothelium (although it is unknown whether PMNs can go through the choroid plexus as well) through receptors located on both endothelial and white blood cell surfaces (33) . Two main groups of surface receptors that are involved in this leukocyte-endothelium interaction have been identified (33, 34) . The first group is the integrin receptor family that is comprised by several a/l heterodimeric transmembrane glycoproteins divided into subfamilies on the basis of structurally distinct # chains. The ,2 subfamily is the most relevant because its receptors are exclusively expressed on leukocytes, and its three members CD1 la/CD18 (LFA-1), CD1 b/CD18 (CR3 or Mac 1), CDl lc/CD18 (p150,95) form the CDl 1/CD18 heterodimer complex. Each ofthese receptor molecules binds to their complementary ligands (ICAM-l or ICAM-2, iC3b, and iC3b, respectively) (33) . The second group of cell surface receptors are called selectins in which the endothelial cell adhesion molecule-1 (ELAM-1) and the leukocyte adhesion molecule (LAM-1) are thought to be also involved in leukocyte attachment to endothelium during acute inflammation (34) . The fact that PMN migration across the blood-brain barrier was effectively blocked by administration of anti-CD 1 8 MAbs indicates, as previously suggested by Tuomanen et al. (6) , that the CD1 1/ CD1 8 receptor family is the most important mechanism by which leukocytes adhere to and traverse the cerebral capillary endothelium. Moreover, it has been already demonstrated that endothelial cells in the CNS express ICAM-1 (35) , one of the CDl 1/CD 1 8 receptor ligands. Whether the selectins are present on brain endothelium is presently unknown but in vitro studies suggest that even when selectins mediate adhesion, integrins are still required for the subsequent event of transendothelial migration (36). This may explain why congenital deficiency ofthe leukocyte integrins so completely inhibits neutrophil emigration from the blood (37) . There is strong evidence supporting the role of cytokines, such as TNF and IL-1, in the activation ofthese receptor complexes (33) . This event could explain, at least in part, the effects of steroids in reducing transendothelial passage of leukocytes into CSF. In agreement with what has been demonstrated in both in vitro and in clinical trials (1, 31) , TNFa concentrations in CSF after bacterial and endotoxin challenge were significantly attenuated when dexamethasone was part of the antiinflammatory regimen. Thus, the profound inhibition in migration of leukocytes across the blood-brain barrier observed in the present study after combining both agents was not an unexpected finding.
This complex cytokine-endothelium-leukocyte interaction is probably responsible for the initial disruption of the barrier by opening intercellular junctions and permitting the passage of serum proteins into the subarachnoidal space. In this regard, the administration of either dexamethasone or anti-CD 1 8 MAbs, and especially of the combination of the two agents, resulted in a significant reduction of CSF protein concentrations compared with the high values detected in animals that received no anti-inflammatory therapy. As shown previously (3) the highest CSF concentrations of protein and leukocytes occurred in the infected rabbits that were treated with antibiotic alone, again emphasizing the abrupt and transient enhanced proinflammatory effect seen consistently in the few hours after initiation of antimicrobial therapy for bacterial meningitis.
The significant reduction of lactate concentrations in CSF in animals that received dexamethasone, either alone or combined with anti-CD 1 8 MAbs, but not anti-CD 1 8 MAbs alone was an unexpected finding. Elevation of lactate concentrations in CSF represents the shift to an anaerobic metabolism as a result of poor oxygen delivery and cerebral tissue perfusion. These pathophysiologic events occur when brain edema and intracranial hypertension compromise cerebral blood flow (38) . At this time it is speculative to postulate that cytokine-induced cellular metabolic abnormalities rather than leukocytemediated events are mostly responsible for increased lactic acid concentrations.
Brain edema occurs in bacterial meningitis as a result of several factors acting in concert: alteration of the blood-brain barrier with subsequent vasogenic edema, cytotoxic activities of activated leukocytes, and interstitial fluid accumulation resulting from increased viscosity of the purulent, protein-rich CSF. The administration ofeach antiinflammatory therapeutic modality reduced substantially brain water content in these experiments, but the maximal effect was observed when dexamethasone and anti-CD 18 MAbs were given concomitantly. 
